Progress towards next-generation therapeutics for cystic fibrosis

Future Medicinal Chemistry

Volumn 6, Issue 9, 2014, Pages 1067-1079

  O'Neil, Deborah A ^a   Fraser Pitt, Douglas ^a  

^a NOVABIOTICS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; ATALUREN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DORNASE ALFA; IVACAFTOR; LUMACAFTOR; MUCOLYTIC AGENT; NITROGEN OXIDE; THIOCYANATE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; AUTOPHAGY; CYSTIC FIBROSIS; GALLBLADDER DISEASE; GENE THERAPY; HUMAN; INNATE IMMUNITY; MICROBIAL COLONIZATION; MUCOLYSIS; PRIORITY JOURNAL; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; REVIEW; GENETICS; METABOLISM; MUTATION;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; MUTATION;

EID: 84905196277     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.67     Document Type: Review

References (100)

1. Muller F, Aubry MC, Gasser B, Duchatel F, Boué J, Boué A. Prenatal diagnosis of cystic fibrosis. II. Meconium ileus in affected fetuses. Prenatal Diagn. 5(2), 109-117 (1985).
2. Farrelly PJ, Charlesworth C, Lee S, Southern KW, Baillie CT. Gastrointestinal surgery in cystic fibrosis: a 20-year review. J. Pediatr. Surg. 49(2), 280-283 (2014).
3. Nash KL, Allison ME, McKeon D, Lomas DJ, Haworth CS, Bilton D, Alexander GJ. A single centre experience of liver disease in adults with cystic fibrosis 1995-2006. J. Cyst. Fibros. 7(3), 252-257 (2007).
4. Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst. Rev. 10, CD000222 (2012).
5. Aanæs K. Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis. J. Cyst. Firbros. 12(Suppl. 2), S1-S20 (2013).
6. Cox MJ, Allgaier M, Taylor B et al. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS ONE 5(6), e11044 (2010).
7. Wolter DJ, Emerson JC, McNamara S et al. Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis. Clin. Infect. Dis. 57(3), 384-391 (2013).
8. Quinn RA, Lim YW, Maughan H, Conrad D, Rohwer F, Whiteson KL. Biogeochemical forces shape the composition and physiology of polymicrobial communities in the cystic fibrosis lung. MBio 5(2), e00956-e01013 (2014).
9. Zach MS, Oberwaldner B. Chest physiotherapy-the mechanical approach to antiinfective therapy in cystic fibrosis. Infection 15(5), 381-384 (1987).
10. Main E, Prasad A, Schans C. Conventional chest physiotherapy compared with other airway clearance techniques in cystic fibrosis. Cochrane Database Syst. Rev. 1, CD002011 (2005).
11. McKoy NA, Saldanha IJ, Odelola OA, Robinson KA. Active cycle of breathing technique for cystic fibrosis. Cochrane Database Syst. Rev. 12, CD007862 (2012).
12. Letham MI, James SL, Marriott C, Burke JF. The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. Eur. Respir. J. 3(1), 19-23 (1990).
13. Rubin B. Mucus, phlegm, and sputum in cystic fibrosis. Respir. Care 54(6), 726-732 (2009).
14. Bragonzi A, Worlitzsch D, Pier GB, Timpert P, Ulrich M, Hentzer M, Andersen JB, Givskov M, Conese M. Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model. J. Infect. Dis. 192(3), 410-419 (2005).
15. Fancello L, Desnues C, Raoult D, Rolain JM. Bacteriophages and diffusion of genes encoding antimicrobial resistance in cystic fibrosis sputum microbiota. J. Antimicrob. Chemother. 66(11), 2448-2454 (2011).
16. Ciofu O, Mandsberg LF, Bjarnsholt T, Wassermann T, H∅iby N. Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology 156(Pt 4), 1108-1119 (2010).
17. Fauvart M1, De Groote VN, Michiels J. Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J. Med. Microbiol. 60(6), 699-709 (2011).
18. Mulcahy LR1, Burns JL, Lory S, Lewis K. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J. Bacteriol. 192(23), 6191-6199 (2010).
19. Moskwa P, Lorentzen D, Excoffon KJ et al. A novel host defense system of airways is defective in cystic fibrosis. Am. J. Respir. Crit. Care Med. 175(2), 174-183 (2007).
20. Zheng S, Xu W, Bose S, Banerjee AK, Haque SJ, Erzurum SC. Impaired nitric oxide synthase-2 signaling pathway in cystic fibrosis airway epithelium. Am. J. Physiol. Lung Cell. Mol. Physiol. 287(2), L374-L381 (2004).
21. Luciani A, Villella VR, Esposito S et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat. Cell. Biol. 12(9), 863-875 (2010).
22. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur. Resp. J. 29, 522-526 (2007).
23. Serisier DJ, Tuck A, Matley D, Carroll MP, Jones G. Antimicrobial susceptibility and synergy studies of cystic fibrosis sputum by direct sputum sensitivity testing. Eur. J. Clin. Microbiol. Infect. Dis. 31(11), 3211-3216.
24. Prayle A, Watson A, Fortnum H, Smyth A. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax 65(7), 654-658 (2010).
25. De Soyza A, Archer L, Wardle J, Parry G, Dark JH, Gould K, Corris PA. Pulmonary transplantation for cystic fibrosis: pre-transplant recipient characteristics in patients dying of peri-operative sepsis. J. Heart Lung Transplant. 22(7), 764-769 (2003).
26. Stutman HR, Lieberman JM, Nussbaum E, Marks MI. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J. Pediatr. 140(3), 299-305 (2002).
27. Ryan G, Singh M, Dwan K. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev. 3, CD001021 (2011).
28. Wagener JS, Rasouliyan L, VanDevanter DR et al. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatr. Pulmonol. 48(7), 666-673 (2013).
29. Cheng K, Smyth RL, Govan JR et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 348(9028),639-642 (1996).
30. Scalley RD, Conner CS. Acetaminophen poisoning: a case report of the use of acetylcysteine. Am. J. Hosp. Pharm. 35(8), 964-967 (1978).
31. Griese M, Kappler M, Eismann C et al. Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am. J. Respir. Crit. Care Med. 188(1), 83-89 (2013).
32. Tam J, Nash EF, Ratjen F, Tullis E, Stephenson A. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst. Rev. 7, CD007168 (2013).
33. Nasr SZ, Chou W, Villa KF, Chang E, Broder MS. Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis. J. Med. Econ. 16(6), 801-808 (2013).
34. Witt DM, Anderson L. Dornase alfa: a new option in the management of cystic fibrosis. Pharmacotherapy 16(1), 40-48 (1996)
35. Wark P, MacDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst. Rev. 2, CD001506 (2009).
36. US FDA. Pulmonary-allergy drugs advisory committee meeting (2013).NDA# 202049: mannitol inhalation powder (proposed trade name Bronchitol) for oral inhalation sponsored by Pharmaxis, for the management of cystic fibrosis (CF) in patients aged 6 years and older to improve pulmonary function. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ Pulmonary-AllergyDrugsAdvisoryCommittee/UCM336995.pdf
37. European Medicines Agency, Committee for Medicinal Products for Human Use (2012). CHMP Assessment Report, Bronchitol® . www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Public-assessment-report/human/001252/WC500130591.pdf
38. National Institute for Health and Clinical Excellence (2012). Mannitol dry powder for inhalation for treating cystic fibrosis [online]. www.nice.org.uk/nicemedia/live/13969/61603/61603.pdf
39. Scottish Medicines Consortium (2013). Mannitol, 400 mg, inhalation powder, hard capsule, (Bronchitol® ). www.scottishmedicines.org.uk/files/ advice/inhaled-mannitol-Bronchitol-FINAL-January-2013-for-website. pdf
40. Bilton D, Daviskas E, Anderson SD et al. A Phase III randomised study of the efficacy and safety of inhaled dry powder mannitol (Bronchitol) for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 144(1), 215-225 (2013).
41. Barraud N, Buson A, Jarolimek W, Rice SA. Mannitol enhances antibiotic sensitivity of persister bacteria in Pseudomonas aeruginosa biofilms. PLoS ONE 8(12), e84220 (2013).
42. LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest 120, 18S-23S (2001).
43. Daniels T, Mills N, Whitaker P. Nebuliser systems for drug delivery in cystic fibrosis. Cochrane Database Syst Rev. 4, CD007639 (2013).
44. Kesser KC, Geller DE. New aerosol delivery devices for cystic fibrosis. Resir. Care. 54(6), 754-767 (2009).
45. Daniels T, Goodacre L, Sutton C, Pollard K, Conway S, Peckham D. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulisers. Chest 140(2), 425-432 (2011).
46. Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology. J. Aerosol. Med. Pulm. Drug Deliv. 24(4), 175-182 (2011).
47. Geller DE, Nasr SZ, Piggott S, He E, Angyalosi G, Higgins M. Tobramycin inhalation powder in cystic fibrosis patients: response by age group. Respir. Care doi: 10.4187/respcare.02264 (2013)
48. de Vrankrijker AM, van der Ent CK, van Berkhout FT et al. Aspergillus fumigatus colonization in cystic fibrosis: implications for lung function? Clin. Microbiol. Infect. 17(9), 1381-1386 (2011).
49. Klemmer A, Krämer I, Kamin W. Physicochemical compatibility and stability of nebulizable drug admixtures containing dornase alfa and tobramycin. Pulm. Pharmacol. Ther. doi:10.1016/j.pupt.2013.08.003 (2013) Epub ahead of print).
50. Silvis MR, Picciano JA, Bertrand C, Weixel K, Bridges RJ, Bradbury NA. A mutation in the cystic fibrosis transmembrane conductance regulator generates a novel internalization sequence and enhances endocytic rates. J. Biol. Chem. 278(13), 11554-11560 (2003).
51. Welch EM, Barton ER, Zhuo J et al. PTC 124 targets genetic disorders caused by nonsense mutations. Nature 447(7140), 87-91 (2007).
52. Rogan MP, Stoltz DA, Hornick DB. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking and opportunities for mutation-specific treatment. Chest 139, 1480-1490 (2011).
53. Kerem E, Hirawat S, Armoni S et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective Phase II trial. Lancet 372(9640), 719-727 (2008).
54. Auld, DS, Thorne N, Maguire WF, Inglese J. Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc. Natl Acad. Sci. USA 106(9), 3585-3590 (2009).
55. Auld DS, Lovell S, Thorne N et al. Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124. Proc Natl Acad Sci. USA 107(11), 4878-4883 (2010).
56. McElroy SP, Nomura T, Torrie LS et al. A lack of premature termination codon read-through. PLoS Biol. 11(6), e1001593 (2013).
57. Sermet-Gaudelus I, Boeck KD, Casimir GJ et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am. J. Respir. Crit. Care Med. 182(10), 1262-1272 (2010).
58. Cystic Fibrosis Foundation, Clinical research information sheet (2012). Ataluren (PTC 124) in Cystic Fibrosis [online]. www.cff.org/UploadedFiles/ ClinicalResearchPDF/CR84.pdf
59. Drake KM, Dunmore BJ, McNelly LN, Morrell NW, Aldred MA. Correction of nonsense BMPR2 and SMAD9 mutations by Ataluren in pulmonary arterial hypertension. Am. J. Respir. Cell. Mol. Biol. 49(3), 403-409 (2013)
60. Li M, Andersson-Lendahl M, Sejersen T, Arner A. Muscle dysfunction and structural defects of dystrophin-null sapje mutant zebrafish larvae are rescued by Ataluren treatment. FASEB J. 28(4), 1593-1599 (2013).
61. Finkel RS, Flanigan KM, Wong B et al. Phase 2a study of Ataluren-mediated dystrophin production in patients with nonsense mutation duchenne muscular dystrophy. PLoS ONE 8(12), e81302 (2013).
62. Rogan MP, Stoltz DA, Hornick DB. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking and opportunities for mutation-specific treatment. Chest 139, 1480-1490 (2011).
63. VanGoor F, Hadida S, Grootenhuis PDRescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770Proc. Natl Acad. Sci. USA.1064418825188302009
64. Eckford PD, Li C, Ramjeesingh M, Bear CE. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J. Biol. Chem. 287(44), 36639-36649 (2012).
65. Jih KY, Hwang TC. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc. Natl Acad. Sci. USA 110(11), 4404-4409 (2013).
66. Ramsey BW, Davies J, McElvaney NG et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365(18), 1663-1672 (2011).
67. Ren HY, Grove DE, De La Rosa O et al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol. Biol. Cell. 24(19), 3016-3024 (2013).
68. Loo TW, Bartlett MC, Clarke DM. Corrector VX-809 stabilizes the first transmembrane domain of CFTR. Biochem. Pharmacol. 86(5), 612-619 (2013).
69. Farinha CM, King-Underwood J, Sousa M et al. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. Chem. Biol. 20(7), 943-955 (2013).
70. He L1, Kota P, Aleksandrov AA, Cui L, Jensen T, Dokholyan NV, Riordan JR. Correctors of ?F508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. FASEB J. 27(2), 536-545 (2013).
71. Rabeh WM, Bossard F, Xu H et al. Correction of both NBD1 energetics and domain interface is required to restore ?F508 CFTR folding and function. Cell 148(1-2), 150-163 (2012).
72. Okiyoneda T1, Veit G, Dekkers JF et al. Mechanism-based corrector combination restores ?F508-CFTR folding and function. Nat. Chem. Biol. 9(7), 444-454 (2013).
73. Clancy JP, Rowe SM, Accurso FJ et al. Results of a Phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67(1), 12-18 (2012).
74. Galietta LJ. Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors. Pediatr. Drugs. 15(5), 393-402 (2013).
75. Farinha CM, King-Underwood J, Sousa M et al. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. Chem. Biol. 20(7), 943-955 (2013).
76. Dowling RB, Newton R, Robichaud A, Cole PJ, Barnes PJ, Wilson R. Effect of inhibition of nitric oxide synthase on Pseudomonas aeruginosa infection of respiratory mucosa in vitro. Am. J. Respir. Cell. Mol. Biol. 19(6), 950-958 (1998).
77. Satoh S, Oishi K, Iwagaki A et al. Dexamethasone impairs pulmonary defence against Pseudomonas aeruginosa through suppressing iNOS gene expression and peroxynitrite production in mice. Clin. Exp. Immunol. 126(2), 266-273 (2001).
78. Brown RK, Kelly FJ. Evidence for increased oxidative damage in patients with cystic fibrosis. Pediatr. Res. 36(4), 487-493 (1994).
79. Brown RK, Wyatt H, Price JF, Kelly FJ. Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress. Eur. Respir. J. 9(2), 334-339 (1996).
80. Michl RK, Hentschel J, Fischer C, Beck JF, Mainz JG. Reduced nasal nitric oxide production in cystic fibrosis patients with elevated systemic inflammation markers. PLoS ONE 8(11), e79141 (2013).
81. Walker WT, Liew A, Harris A, Cole J, Lucas JS. Upper and lower airway nitric oxide levels in primary ciliary dyskinesia, cystic fibrosis and asthma. Respir. Med. 107(3), 380-386 (2013).
82. Grasemann H, Schwiertz R, Matthiesen S, Racké K, Ratjen F. Increased arginase activity in cystic fibrosis airways. Am. J. Respir. Crit. Care Med. 172(12), 1523-1528 (2005).
83. Grasemann H, Schwiertz R, Grasemann C, Vester U, Racké K, Ratjen F. Decreased systemic bioavailability of L-arginine in patients with cystic fibrosis. Respir. Res. 7, 87 (2006).
84. Everard ML, Donnelly D. A pilot study of oral L-arginine in cystic fibrosis. J. Cyst. Fibros. 4(1), 67-69 (2005).
85. Grasemann H, Grasemann C, Kurtz F, Tietze-Schillings G, Vester U, Ratjen F. Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study. Eur. Respir. J. 25(1), 62-68 (2005).
86. Grasemann H, Tullis E, Ratjen F. A randomized controlled trial of inhaled L-arginine in patients with cystic fibrosis. J. Cyst. Fibros. 12(5), 468-474 (2013).
87. Miller CC, Hergott CA, Rohan M, Arsenault-Mehta K, Döring G, Mehta S. Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumonia. J. Cyst. Fibros. 12(6), 817-820 (2013).
88. Hopkins N, Gunning Y, O'Croinin DF, Laffey JG, McLoughlin P. Anti-inflammatory effect of augmented nitric oxide production in chronic lung infection. J. Pathol. 209(2), 198-205 (2006).
89. Chandler JD, Min E, Huang J, Nichols DP, Day BJ. Nebulized thiocyanate improves lung infection outcomes in mice. Br. J. Pharmacol. 169(5), 1166-1177 (2013).
90. Levine B, Kroemer G. Autophagy in aging, disease and death: the true identity of a cell death impostor. Cell Death Differ. 16(1), 1-2 (2009).
91. Junkins RD, Shen A, Rosen K, McCormick C, Lin TJ. Autophagy enhances bacterial clearance during P. aeruginosa lung infection. PLoS ONE 8(8), e72263 (2013).
92. Rich DP, Anderson MP, Gregory RJ et al. Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 347(6291), 358-363 (1990).
93. Caplen NJ, Gao X, Hayes P et al. Gene therapy for cystic fibrosis in humans by liposome-mediated DNA transfer: the production of resources and the regulatory process. Gene Ther. 1(2), 139-147 (1994).
94. Johnson LG. Gene therapy for cystic fibrosis. Chest 107(2 Suppl.), 77S-83S (1995).
95. Lehrman S. Virus treatment questioned after gene therapy death. Nature 401(6753), 517-518 (1999).
96. Horsley AR, Davies JC, Gray RD, Macleod KA, Donovan J, Aziz ZA, Bell NJ, Rainer M, Mt-Isa S, Voase N, Dewar MH, Saunders C, Gibson JS, Parra-Leiton J, Larsen MD, Jeswiet S, Soussi S, Bakar Y, Meister MG, Tyler P, Doherty A, Hansell DM, Ashby D, Hyde SC, Gill DR, Greening AP, Porteous DJ, Innes JA, Boyd AC, Griesenbach U, Cunningham S, Alton EW. Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. Thorax 68(6), 532-539 (2013).
97. Kent L, Reix P, Innes JA et al. Lung clearance index: evidence for use in clinical trials in cystic fibrosis. J. Cyst. Fibros. 13(2), 123-138 (2014).
98. Alton EW, Boyd AC, Cheng SH et al. A randomised, double-blind, placebo-controlled Phase IIb clinical trial of repeated application of gene therapy in patients with cystic fibrosis. Thorax 68(11), 1075-1077 (2013).
99. Junkins RD, McCormick C, Lin TJ. The emerging potential of autophagy-based therapies in the treatment of cystic fibrosis lung infections. Autophagy 10(3), 538-547 (2014).
100. Lee TW, Southern KW. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disdisease. Cochrane Database Syst Rev. 11, CD005599 (2013).